You are here

Shire

FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire

Endpoints

Fri, 06/23/17 - 09:48 am

hereditary angiodema

A decade behind schedule, Shire finally gets an FDA OK for long-acting ADHD drug

Endpoints

Wed, 06/21/17 - 09:50 am

Kamada slumps after Shire hands back rights

BioPharma Dive

Thu, 06/8/17 - 10:05 pm

alpha-1 antitrypsin

graft vs host disease

Shire Is Poised To Dominate The HAE Market After Strong Phase III Data For SHP643

Seeking Alpha

Mon, 05/22/17 - 07:43 pm

Shire writes off a shot at long-acting hemophilia drug after small study flops

Endpoints

Mon, 05/22/17 - 09:55 am

Xenetic Biosciences

clinical trials

Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application

Endpoints

Thu, 05/18/17 - 09:38 am

Shire commits up to $535M for Parion's dry eye drug

BioPharma Dive

Tue, 05/2/17 - 11:16 am

dry eye disease

Shire, armed with new rare disease patent, aims to block CSL's Haegarda launch

Fierce Pharma

Mon, 04/17/17 - 04:10 pm

hereditary angiodema

Shire's DTC move to scrap smiling patients for double 'i's pays off—and it thinks other pharmas should take note

Fierce Pharma

Thu, 04/13/17 - 09:39 am

dry eye disease

About that pharma M&A comeback? Sorry. 2017's not bringing it—at least not yet

Fierce Pharma

Mon, 04/10/17 - 10:19 am

Ariad Pharmaceuticals

Shire Rises on Encouraging Angioedema Results

TheStreet.com

Thu, 02/23/17 - 09:25 pm

2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals

Endpoints

Wed, 02/22/17 - 11:43 am

Baxalta pushes Shire to record revenues

BioPharma Dive

Thu, 02/16/17 - 03:18 pm

Shire finally finishes a 10-year trek back to the FDA with an old ADHD drug

Endpoints

Thu, 01/19/17 - 11:49 am

Shire to pay $350 million for kickback allegations

Marketwatch

Thu, 01/12/17 - 09:14 am

False Claims Act

Shire deals RNA platform to Cambridge's RaNa for equity stake

Bizjournals.com

Wed, 01/4/17 - 10:44 am

drug development

Allergan Is Losing Its No. 2 Product More Rapidly Than Expected

Seeking Alpha

Wed, 12/21/16 - 10:53 am

dry eye disease

The Most Expensive Drugs of 2016

Motley Fool

Mon, 12/19/16 - 11:32 am

Gilead Sciences

Bristol-Myers Squibb

Shire's Vonvendi controls surgical bleeding

BioPharma Dive

Mon, 12/5/16 - 01:31 pm

surgical bleeding

Allergan's Restasis Faces Dry Eye Threat: Examining XIIDRA's Initial Sales Trends

Seeking Alpha

Tue, 11/8/16 - 10:09 am

dry eye disease

Pages